<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00728208</url>
  </required_header>
  <id_info>
    <org_study_id>105467</org_study_id>
    <nct_id>NCT00728208</nct_id>
  </id_info>
  <brief_title>GSK372475 PK Study in Healthy Volunteers</brief_title>
  <official_title>A Placebo-controlled, Single-blind, Randomised, Parallel Group, 28-day Repeat Dose Study to Investigate the Tolerability, Safety and Steady State Pharmacokinetics of GSK372475 in Healthy Young and Elderly, Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will consist of 4 parallel cohorts of healthy volunteers (elderly male, elderly&#xD;
      female, young male and young female). Subjects will receive either GSK372475 1.5mg or placebo&#xD;
      for 28 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2008</start_date>
  <completion_date type="Actual">December 29, 2008</completion_date>
  <primary_completion_date type="Actual">December 29, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Main pharmacokinetic parameters after single and repeat administration: Cmax, tmax, AUC(0-t), AUC(0-tau), Ctau and Ro.</measure>
    <time_frame>pre-dose to 24 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability endpoints, including adverse events (AEs), vital signs, electrocardiograms (ECGs) and clinical laboratory tests.</measure>
    <time_frame>from dosing to follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>GSK372475</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK372475</intervention_name>
    <description>1.5mg for 28 days</description>
    <arm_group_label>GSK372475</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy as determined by a responsible physician, based on a medical evaluation&#xD;
             including medical and psychiatric history (including family history), full physical&#xD;
             examination, laboratory tests and cardiac monitoring.&#xD;
&#xD;
          -  Male or female between 18 and 45 years of age (young healthy population) and &gt;65 years&#xD;
             old (elderly population).&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of:&#xD;
&#xD;
          -  Non-childbearing potential defined as pre-menopausal females with a documented tubal&#xD;
             ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous&#xD;
             amenorrhea&#xD;
&#xD;
          -  Child-bearing potential and agrees to use of specific contraception methods. Use of&#xD;
             oral contraception is permitted.&#xD;
&#xD;
          -  BMI within the range 19 - 29 kg/m2 (inclusive).&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  QTcB or QTcF &lt; 450 msec; or QTc &lt; 480 msec in subjects with Bundle Branch Block.&#xD;
&#xD;
          -  Able to swallow and retain oral medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject will not be eligible for inclusion in this study if any of the following&#xD;
             criteria apply:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular or other heart disease, glaucoma,&#xD;
             diabetes, hepatic, neurologic (e.g. including but not limited to seizures, stroke,&#xD;
             cerebrovascular disease or other brain conditions), or allergic disease (except for&#xD;
             untreated, asymptomatic, seasonal allergies at time of dosing).&#xD;
&#xD;
          -  Psychiatric illness currently or within the past year, or any lifetime history of&#xD;
             bipolar disorder, major depressive disorder, anxiety disorder, schizophrenia or other&#xD;
             psychotic disorder, or substance abuse or dependence (except past history of nicotine&#xD;
             abuse/dependence).&#xD;
&#xD;
          -  Subjects who, in the investigator's judgment, pose a suicidal or homicidal risk, or&#xD;
             any subject with a history of suicidal or homicidal attempts or behaviour.&#xD;
&#xD;
          -  The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that&#xD;
             will be screened for include amphetamines, barbiturates, cocaine, opiates,&#xD;
             cannabinoids and benzodiazepines.&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening (with the exception of phase I hepatic impairment&#xD;
             studies, oncology studies, hepatitis, hepatic fibrosis, or HIV studies).&#xD;
&#xD;
          -  A positive test for HIV antibody.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as:&#xD;
&#xD;
          -  an average weekly intake of greater than 21 units or an average daily intake of&#xD;
             greater than 3 units (males), or defined as an average weekly intake of greater than&#xD;
             14 units or an average daily intake of greater than 2 units (females). One unit is&#xD;
             equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass&#xD;
             (125ml) of wine.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 60 days i.e. 5 half-lives.&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study medication, unless in the opinion of the Investigator and GSK Medical&#xD;
             Monitor the medication will not interfere with the study procedures or compromise&#xD;
             subject safety.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period.&#xD;
&#xD;
          -  Pregnant females as determined by positive serum or urine hCG test at screening or&#xD;
             prior to dosing.&#xD;
&#xD;
          -  Lactating females.&#xD;
&#xD;
          -  Administration of a monoamine oxidase inhibitor (MAOI) within 30 days prior to Study&#xD;
             Day 1, or anticipated use within 12 weeks following the last dose of study drug.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Consumption of grapefruit juice or grapefruit or cruciferous vegetables (e.g.&#xD;
             broccoli, Brussels sprouts, cabbage, cauliflower, chard, kale, mustard greens,&#xD;
             rutabagas and turnips) and charbroiled foods within 7 days prior to first dose of&#xD;
             study medication until follow-up.&#xD;
&#xD;
          -  Controlled or uncontrolled hypertension, or systolic blood pressure ≥140 mmHg or&#xD;
             diastolic blood pressure ≥90 mmHg at screening or prior to the first dose of study&#xD;
             medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>August 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2008</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Young</keyword>
  <keyword>Elderly</keyword>
  <keyword>Randomised</keyword>
  <keyword>GSK372475</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

